BIOSYNTECH Inc. Shareholders Approve Merger.

Business Editors

MONTREAL--(BUSINESS WIRE)--Feb. 7, 2000

BIOSYNTECH Inc (OTCBB:BSYI)(formerly dream team international Inc) announces that its merger with BIOSYNTECH Canada Inc has been approved by the shareholders of BIOSYNTECH Canada Inc and is expected to close on or before february 11, 2000. Following the completion of the merger, BIOSYNTECH Inc will issue to the former shareholders of BIOSYNTECH Canada up to 16,696,440 shares of its common stock, which will give BIOSYNTECH Inc a total issued and outstanding capital of up to 28,696,440 shares of common stock.

Following the completion of the merger, the board of BIOSYNTECH Inc will be composed of amine selmani, denis beaudry, pierre alary and jean-yves bourgeois.

Mr amine selmani, chairman and chief executive officer of BIOSYNTECH, has further announced the conclusion of a private placement pursuant to which a total of 400,000 units of BIOSYNTECH Inc will be issued at a price of $5.00 per unit. Each unit is comprised of one share of BIOSYNTECH's common stock and one warrant entitling the holder to acquire one share of common stock at a price of $7.00 for a period of 18 months. Closing of the private placement is conditional on the closing of the merger.

BIOSYNTECH Canada is a montreal based company which has developed a number of platform technologies aimed at the generation of innovative solutions to efficiently deliver biologically active therapeutics. The resulting proprietary technologies offer a range of delivery vehicles with unmatched properties in a broad range of applications. The attributes of BIOSYNTECH's portfolio of biomaterials are especially adapted for the new generation of therapeutics such as recombinant proteins, genetic material and living cells. Biosyntech has developed four main technology platforms: i) injectable thermos-sensitive self-forming hydrogel for therapeutics delivery; ii) solvent and detergent-free micro-spheres for drug delivery; iii) chondrocytes delivered arthroscopically in an adhesive exogenous matrix for the treatment of cartilage defects; and iv) bone filling materials and injectable calcium-phosphate for the prevention of hip fractures due to osteoporosis.

Biosyntech's common stock is traded under the symbol &uot;bsyi&uot; on the over-the-counter bulletin board (otc bb).

This press release contains certain &uot;forward-looking&uot; statements, as defined in the united states private securities litigation reform act of 1995, that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in the company's filings with the regulatory authorities having jurisdiction.

No regulatory authority has approved or disapproved the content of this release.